Tubidy
    Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLC

    Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLC

    03:57 |
    Download MP3

    Related Videos

    VJOncology at BTOG 2023 0:34

    VJOncology at BTOG 2023

    Active surveillance in localized prostate cancer 4:12

    Active surveillance in localized prostate cancer

    Combining radiotherapy with novel agents in NSCLC 0:47

    Combining radiotherapy with novel agents in NSCLC

    The use of photopheresis for the treatment of cutaneous T-cell lymphoma 3:22

    The use of photopheresis for the treatment of cutaneous T-cell lymphoma

    Clinical targeting of adaptive resistance in colorectal cancer 0:40

    Clinical targeting of adaptive resistance in colorectal cancer

    Current challenges and key developments in CRC 4:00

    Current challenges and key developments in CRC

    Hormone receptor status and tumor subtypes in BRCA-variant breast cancer 1:26

    Hormone receptor status and tumor subtypes in BRCA-variant breast cancer

    Advances in salvage radiotherapy for prostate cancer 1:23

    Advances in salvage radiotherapy for prostate cancer

    KEYNOTE-775 subgroup analysis in advanced endometrial cancer 3:28

    KEYNOTE-775 subgroup analysis in advanced endometrial cancer

    Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab 2:58

    Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

    The role of PSMA PET in recurrent prostate cancer 3:50

    The role of PSMA PET in recurrent prostate cancer

    ETOP clinical trials in EGFR-, KRASG12C- and ALK-mutated NSCLC 2:47

    ETOP clinical trials in EGFR-, KRASG12C- and ALK-mutated NSCLC

    Quantifying time toxicity in lung cancer trials with Time Toxicity Units 1:30

    Quantifying time toxicity in lung cancer trials with Time Toxicity Units

    Biomarker detection for early cancer detection 2:03

    Biomarker detection for early cancer detection

    Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC 2:52

    Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

    Metastatic TNBC at ESMO Breast 2024: IMpassion132 and MORPHEUS 1:05

    Metastatic TNBC at ESMO Breast 2024: IMpassion132 and MORPHEUS

    Unanswered questions in treating NSCLC with radiotherapy 2:27

    Unanswered questions in treating NSCLC with radiotherapy

    MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC 4:03

    MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC

    Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer 1:49

    Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer

    ADCs for lung cancer 1:49

    ADCs for lung cancer